v3.26.3
SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
REVENUE $ 47,917 $ 2,543,823 $ 146,915 $ 6,941,151
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively) (43,429) (2,166,138) (130,235) (5,851,951)
GROSS PROFIT 4,488 377,685 16,680 1,089,200
Interest income 16,541 20,778 54,903 74,114
Other income 6,239 40,414 22,779 147,231
Sales and marketing (35,007) (551,569) (123,762) (1,700,691)
Research and development (13,578) (14,876) (41,736) (39,572)
Fair value loss on investments in equity securities     0 (91,243)
Share-based compensation 799,998 0 799,998 0
TOTAL OPERATING EXPENSES (1,084,249) (1,191,054) (1,985,252) (3,344,869)
(LOSS)/PROFIT FROM OPERATIONS (1,052,579) (705,609) (1,880,825) (1,941,940)
FINANCE COSTS (1,801) (3,382) (3,581) (6,550)
Loss before income taxes, amount (1,054,380) (708,991) (1,884,406) (1,948,490)
Tax expense 0 0 0 0
Fair value loss on investments in equity securities     0 91,243
Share-based compensation $ (799,998) $ 0 (799,998) 0
Trading Of Industrial Chemicals [Member]        
REVENUE     144,954 6,929,849
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     (128,985) (5,846,956)
GROSS PROFIT     15,969 1,082,893
Dividend income       21,752
Interest income     16,630 10,468
Gain from foreign exchange     1,790  
Other income     22,779 136,312
Fair value gain on investments in equity securities       28,256
Gain on disposal of investments in equity securities       42,376
TOTAL OTHER INCOME     41,199 239,164
Sales and marketing     (2,790) (1,577,214)
Research and development     0 0
General and administrative     (162,031) (492,464)
Fair value loss on investments in equity securities       (119,499)
Provision for expected credit losses     (76,814) (121,030)
Share-based compensation     0  
TOTAL OPERATING EXPENSES     (241,635) (2,310,207)
(LOSS)/PROFIT FROM OPERATIONS     (184,467) (988,150)
FINANCE COSTS     (1,574) (6,266)
Loss before income taxes, amount     (186,041) (994,416)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (186,041) (994,416)
Fair value loss on investments in equity securities       119,499
Gain on disposal of investments in equity securities       (42,376)
Share-based compensation     0  
Provision For Genomic Screening Services [Member]        
REVENUE     1,961 11,302
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     (1,250) (4,995)
GROSS PROFIT     711 6,307
Dividend income       0
Interest income     38,273 63,646
Gain from foreign exchange     8,227  
Other income     0 10,919
Fair value gain on investments in equity securities       0
Gain on disposal of investments in equity securities       0
TOTAL OTHER INCOME     46,500 74,565
Sales and marketing     (98,154) (86,275)
Research and development     (41,736) (39,572)
General and administrative     (180,877) (270,725)
Fair value loss on investments in equity securities       0
Provision for expected credit losses     0 0
Share-based compensation     0  
TOTAL OPERATING EXPENSES     (320,767) (396,572)
(LOSS)/PROFIT FROM OPERATIONS     (273,556) (315,700)
FINANCE COSTS     0 (32)
Loss before income taxes, amount     (273,556) (315,732)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (273,556) (315,732)
Fair value loss on investments in equity securities       0
Gain on disposal of investments in equity securities       0
Share-based compensation     0  
Investment Holding [Member]        
REVENUE     0 0
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     0 0
GROSS PROFIT     0 0
Dividend income       0
Interest income     0 0
Gain from foreign exchange     48  
Other income     0 0
Fair value gain on investments in equity securities       0
Gain on disposal of investments in equity securities       0
TOTAL OTHER INCOME     48 0
Research and development     0 0
General and administrative     (600,034) (600,888)
Fair value loss on investments in equity securities       0
Provision for expected credit losses     0 0
Share-based compensation     (799,998)  
TOTAL OPERATING EXPENSES     (1,422,850) (638,090)
(LOSS)/PROFIT FROM OPERATIONS     (1,422,802) (638,090)
FINANCE COSTS     (2,007) (252)
Loss before income taxes, amount     (1,424,809) (638,342)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (1,424,809) (638,342)
Fair value loss on investments in equity securities       0
Gain on disposal of investments in equity securities       0
Share-based compensation     799,998  
Sales and marketing     (22,818) (37,202)
Foreign, Malaysia        
REVENUE     146,915 6,941,151
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     (130,235) (5,851,951)
GROSS PROFIT     16,680 1,089,200
Dividend income       21,752
Interest income     54,903 74,114
Gain from foreign exchange     10,017  
Other income     22,779 147,231
Fair value gain on investments in equity securities       119,499
Gain on disposal of investments in equity securities       42,376
TOTAL OTHER INCOME     87,699 313,729
Sales and marketing     (100,944) (1,663,489)
Research and development     (41,736) (39,572)
General and administrative     (342,908) (763,189)
Fair value loss on investments in equity securities       (28,256)
Provision for expected credit losses     (76,814) (121,030)
Share-based compensation     0  
TOTAL OPERATING EXPENSES     (562,402) (2,706,779)
(LOSS)/PROFIT FROM OPERATIONS     (458,023) (1,303,850)
FINANCE COSTS     (1,574) (6,298)
Loss before income taxes, amount     (459,597) (1,310,148)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (459,597) (1,310,148)
Fair value loss on investments in equity securities       28,256
Gain on disposal of investments in equity securities       (42,376)
Share-based compensation     0  
United States of America        
REVENUE     0 0
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     0 0
GROSS PROFIT     0 0
Dividend income       0
Interest income     0 0
Gain from foreign exchange     48  
Other income     0  
Fair value gain on investments in equity securities       0
Gain on disposal of investments in equity securities       0
TOTAL OTHER INCOME     48 0
Sales and marketing     (22,818) (37,202)
Research and development     0 0
General and administrative     (600,034) (600,888)
Fair value loss on investments in equity securities       0
Provision for expected credit losses     0 0
Share-based compensation     799,998  
TOTAL OPERATING EXPENSES     (1,422,850) (638,090)
(LOSS)/PROFIT FROM OPERATIONS     (1,422,802) (638,090)
FINANCE COSTS     (2,007) (252)
Loss before income taxes, amount     (1,424,809) (638,342)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (1,424,809) (638,342)
Fair value loss on investments in equity securities       0
Gain on disposal of investments in equity securities       0
Share-based compensation     (799,998)  
By Business Unit        
REVENUE     146,915 6,941,151
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     (130,235) (5,851,951)
GROSS PROFIT     16,680 1,089,200
Dividend income       21,752
Interest income     54,903 74,114
Gain from foreign exchange     10,065  
Other income     22,779 147,231
Fair value gain on investments in equity securities       28,256
Gain on disposal of investments in equity securities       42,376
TOTAL OTHER INCOME     87,747 313,729
Sales and marketing     (123,762) (1,700,691)
Research and development     (41,736) (39,572)
General and administrative     (942,942) (1,364,077)
Fair value loss on investments in equity securities       (119,499)
Provision for expected credit losses     (76,814) (121,030)
Share-based compensation     (799,998)  
TOTAL OPERATING EXPENSES     (1,985,252) (3,344,869)
(LOSS)/PROFIT FROM OPERATIONS     (1,880,825) (1,941,940)
FINANCE COSTS     (3,581) (6,550)
Loss before income taxes, amount     (1,884,406) (1,948,490)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (1,884,406) (1,948,490)
Fair value loss on investments in equity securities       119,499
Gain on disposal of investments in equity securities       (42,376)
Share-based compensation     799,998  
By Country        
REVENUE     146,915 6,941,151
COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively)     (130,235) (5,851,951)
GROSS PROFIT     16,680 1,089,200
Dividend income       21,752
Interest income     54,903 74,114
Gain from foreign exchange     10,065  
Other income     22,779 147,231
Fair value gain on investments in equity securities       28,256
Gain on disposal of investments in equity securities       42,376
TOTAL OTHER INCOME     87,747 313,729
Sales and marketing     (123,762) (1,700,691)
Research and development     (41,736) (39,572)
General and administrative     (942,942) (1,364,077)
Fair value loss on investments in equity securities       (119,499)
Provision for expected credit losses     (76,814) (121,030)
Share-based compensation     799,998  
TOTAL OPERATING EXPENSES     (1,985,252) (3,344,869)
(LOSS)/PROFIT FROM OPERATIONS     1,880,825 (1,941,940)
FINANCE COSTS     (3,581) (6,550)
Loss before income taxes, amount     (1,884,406) (1,948,490)
Tax expense     0 0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS     (1,884,406) (1,948,490)
Fair value loss on investments in equity securities       119,499
Gain on disposal of investments in equity securities       $ (42,376)
Share-based compensation     $ (799,998)